Literature DB >> 15569785

Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis.

Asrat Hailu1, Tom van der Poll, Nega Berhe, Piet A Kager.   

Abstract

Interferon (IFN)- gamma plays an important role during immune responses against leishmaniasis. Production of IFN-gamma is regulated by interleukin (IL)-12, IL-18, and IL-15. Interferon-gamma-inducible protein (IP)-10 and monokine induced by IFN-gamma (Mig) are CXC chemokines, the production of which, at least in part, is IFN-gamma dependent. A follow-up study of individuals infected with Leishmania donovani was undertaken in an area of Ethiopia endemic for visceral leishmaniasis (VL). Plasma levels of IFN-gamma, IL-12p40, IL-18, IL-15, IP-10, and Mig were markedly elevated in symptomatic VL patients (n = 70) compared with individuals with asymptomatic Leishmania infections (n = 39), malaria patients (n = 13), and healthy controls from the endemic area (n = 12). A significant decrease of IFN-gamma and all mediators was observed after treatment of VL patients (n = 33). These data show that increased plasma levels of IFN-gamma, as well as the mediators involved in the production and the activity of this cytokine, are characteristic of active VL in humans, and may play an important immunopathogenic role. The data also suggest that in patients with VL, the production of type 1 cytokines is not depressed, but there appears to be an unresponsiveness to the stimuli of type 1 cytokines. The underlying causes of immunologic unresponsiveness remain a subject of further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569785

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  29 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Authors:  M S Duthie; J Guderian; A Vallur; A Bhatia; P Lima dos Santos; E Vieira de Melo; A Ribeiro de Jesus; M Todt; D Mondal; R Almeida; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

Review 3.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

Review 4.  Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Authors:  Lynn Soong; Calvin A Henard; Peter C Melby
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

Review 5.  Role of chemokines in regulation of immunity against leishmaniasis.

Authors:  Steve Oghumu; Claudio M Lezama-Dávila; Angelica P Isaac-Márquez; Abhay R Satoskar
Journal:  Exp Parasitol       Date:  2010-03-03       Impact factor: 2.011

6.  CXCR3 in T cell function.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

7.  Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.

Authors:  I Best; V Adaui; K Verdonck; E González; M Tipismana; D Clark; E Gotuzzo; G Vanham
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

8.  CXCL10 production by human monocytes in response to Leishmania braziliensis infection.

Authors:  Diego A Vargas-Inchaustegui; Alison E Hogg; Gianfranco Tulliano; Alejandro Llanos-Cuentas; Jorge Arevalo; Janice J Endsley; Lynn Soong
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

9.  Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.

Authors:  Sandeep Verma; Rajesh Kumar; Gajendra Kumar Katara; Laishram Chandreshwor Singh; Narender Singh Negi; V Ramesh; Poonam Salotra
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

10.  Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.

Authors:  Ghassem Solgi; Amina Kariminia; Khossor Abdi; Majid Darabi; Behnaz Ghareghozloo
Journal:  Korean J Parasitol       Date:  2006-03       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.